Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | AKR1C1 | Q04828 | 7/20 | 0.55 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6169411 | 1.00 | ALDH1A1 (0.55) | ALDH1A1HTTAKR1C1AKR1C2AKR1C3 | |
| SCHEMBL11079768 | 0.93 | HTT (0.55) | ALDH1A1HTTAKR1C1AKR1C2AKR1C3 | |
| SCHEMBL11079773 | 0.93 | HTT (0.55) | ALDH1A1HTTAKR1C1AKR1C2AKR1C3 | |
| SCHEMBL5183481 | 0.87 | AKR1C1 (0.70) | ALDH1A1HTTAKR1C1AKR1C2AKR1C3 | |
| SCHEMBL7992874 | 0.87 | AKR1C1 (0.70) | ALDH1A1HTTAKR1C1AKR1C2AKR1C3 | |
| SCHEMBL6172379 | 0.87 | AKR1C1 (0.70) | ALDH1A1HTTAKR1C1AKR1C2AKR1C3 | |
| SCHEMBL7814857 | 0.86 | AKR1C1 (0.75) | ALDH1A1HTTAKR1C1AKR1C2AKR1C3 | |
| SCHEMBL11328602 | 0.86 | AKR1C1 (0.75) | ALDH1A1HTTAKR1C1AKR1C2AKR1C3 | |
| SCHEMBL28584154 | 0.86 | ALDH1A1 (0.58) | ALDH1A1HTTAKR1C1AKR1C2AKR1C3 | |
| SCHEMBL6168722 | 0.84 | AKR1C1 (0.56) | ALDH1A1HTTAKR1C1AKR1C2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397652-A2 | 3-(PHENYL)-2-(AMINOMETHYL)-1-PHENYL-2-PROPEN-1-ONE DERIVATIVES AS INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR FOR TREATING PROSTATE CANCER | The Regents of the University of California (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-110325508-B | Inhibitors of the N-terminal domain of androgen receptor | 加利福尼亚大学董事会 | 2023-06-30 | — | — | CN | disclosed |
| US-20220177418-A1 | INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-09 | — | — | US | disclosed |
| WO-2020205470-A1 | INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2018136792-A1 | INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-26 | — | — | WO | disclosed |
| EP-1528059-A2 | Substituted isoxazoles for the treatment of inflammation | G.D. Searle LLC (US) | 2005-05-04 | — | — | EP | disclosed |
| EP-0809636-B1 | SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-1223167-A2 | Substituted isoxazoles for the treatment of inflammation | G.D. Searle & Co. (US) | 2002-07-17 | — | — | EP | disclosed |
| US-5859257-A | ANTIINFLAMMATORY, ANTIARTHRITIC AGENTS | G. D. SEARLE & CO. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0809636-A1 | SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1996025405-A1 | SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177418-A1 | INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR | AR, BRDT, NR5A1 | ALDH1A1 3042/4885HTT 4265/4885AKR1C1 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.